P2x4 receptor antagonist
US-2018201587-A1 · Jul 19, 2018 · US
UBE2K modulators and methods for their use
US11091447B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11091447-B2 |
| Application number | US-202017139188-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 31, 2020 |
| Priority date | Jan 3, 2020 |
| Publication date | Aug 17, 2021 |
| Grant date | Aug 17, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are compounds of Formula (I):and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of the Formula: or a pharmaceutically acceptable salt of any of the foregoing. 2. The compound of claim 1 , wherein the compound is of the Formula: or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein the compound is of the Formula: or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 , wherein the compound is of the Formula: or a pharmaceutically acceptable salt thereof. 5. A pharmaceutical composition comprising a compound of the Formula: or a pharmaceutically acceptable salt of any of the foregoing; and a pharmaceutically acceptable carrier. 6. The composition of claim 5 , wherein the compound is of the Formula: or a pharmaceutically acceptable salt thereof. 7. The composition of claim 5 , wherein the compound is of the Formula: or a pharmaceutically acceptable salt thereof. 8. The composition of claim 5 , wherein the compound is of the Formula: or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Oxygen or sulfur atoms · CPC title
containing three or more hetero rings · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11091447B2 cover?
- Provided are compounds of Formula (I):and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.
- Who is the assignee on this patent?
- Berg Llc
- What technology area does this patent fall under?
- Primary CPC classification C07D409/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).